Neola Medical AB (publ) develops the first medical device for non-invasive continuous monitoring of lungs of preterm born babies, Neola® (Neonatal Lung Analyzer). Immediate detection of pulmonary complications provides the possibility of early treatment and improved health care. The patented technology is safe for the infant’s vulnerable skin and it is based on a spectroscopic method developed at Lund University in Sweden. The company was founded in 2016 as a wholly owned subsidiary of Gasporox AB (publ) under the name GPX Medical AB. The company is listed on NASDAQ First North Growth Market (ticker: NEOLA).
Three qualities about Neola®:
- Faster detection of pulmonary complications preventing further major morbidities
- Decreased number of days in the expensive neonatal intensive care unit
- Decreased time for visual observation by nurses